Cassava Sciences, Inc. (SAVA) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Cassava Sciences, Inc. (SAVA) Bundle
Engineered for accuracy, our (SAVA) DCF Calculator enables you to assess the valuation of Cassava Sciences, Inc. with real-world financial data and complete flexibility to modify all essential parameters for improved projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | -100 | -25 | -25 | -25 | -25 | -25 |
| EBITDA | -4.6 | -6.3 | -31.9 | -74.9 | -95.7 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 4163611.11 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .1 | .0 | .5 | 1.3 | 1.5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | -72277.78 | 100 | 60 | 60 | 60 | 60 | 60 |
| EBIT | -4.6 | -6.3 | -32.4 | -76.2 | -97.2 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 4235888.89 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 23.1 | 93.5 | 233.4 | 201.0 | 121.1 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | -11.2 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | 1.0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 0 | 100 | 80 | 80 | 80 | 80 | 80 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 0 | 100 | 80 | 80 | 80 | 80 | 80 |
| Accounts Payable | .5 | .9 | 7.1 | 4.0 | 10.6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | -223166.67 | 100 | 60 | 60 | 60 | 60 | 60 |
| Capital Expenditure | .0 | .0 | -22.2 | -2.7 | -.4 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 150666.67 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -4.2 | -5.9 | -31.8 | -72.5 | -97.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -3.8 | -5.4 | -47.3 | -77.0 | -90.5 | -9.6 | .0 | .0 | .0 | .0 |
| WACC, % | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -9.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -9 | |||||||||
| Net Debt | -121 | |||||||||
| Equity Value | 112 | |||||||||
| Diluted Shares Outstanding, MM | 42 | |||||||||
| Equity Value Per Share | 2.67 |
What You Will Get
- Real SAVA Financial Data: Pre-filled with Cassava Sciences' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Cassava Sciences' intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Cassava Sciences, Inc. (SAVA).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to SAVA.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates as needed.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Cassava Sciences, Inc. (SAVA).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Cassava Sciences data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Cassava Sciences’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Cassava Sciences, Inc. (SAVA)?
- Accurate Data: Real Cassava Sciences financials provide dependable valuation outcomes.
- Customizable: Modify key metrics such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-built calculations save you from starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Intuitive design and step-by-step guidance make it accessible for all users.
Who Should Use This Product?
- Biotech Students: Explore drug development processes and apply theoretical knowledge using real-world data.
- Researchers: Integrate innovative models into studies focusing on neurodegenerative diseases.
- Investors: Evaluate your own hypotheses and assess valuation metrics for Cassava Sciences, Inc. (SAVA).
- Market Analysts: Enhance your analysis with a customizable financial model tailored for biotech companies.
- Healthcare Professionals: Understand how public biotech firms like Cassava Sciences are evaluated in the market.
What the Template Contains
- Historical Data: Includes Cassava Sciences, Inc. (SAVA)’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Cassava Sciences, Inc. (SAVA)’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Cassava Sciences, Inc. (SAVA)’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.